Skip to main content

Monoterpenes as Perspective to Chronic Pain Management: A Systematic Review

Buy Article:

$68.00 + tax (Refund Policy)

Background: Individuals with chronic diseases have persistent pain as the main symptom, which can often reduce their life quality and functional capacity. The suffering of patients results from the interaction of aversive perception of pain with physical disability, social and family isolation, financial worries and fear of mutilation and death. As an individual and subjective phenomenon that involves many complex aspects, chronic pain should be evaluated and treated in its various components. Several drugs are currently used, but besides the high cost, they have side effects that are harmful to patients. Therefore, there is the need to search for new options for pain relief. Natural products as monoterpenes have been the target of many researchers.

Objective: This systematic review aimed to briefly summarize the knowledge of the analgesic potential of monoterpenes facing chronic pain.

Results: After a search in PubMed, Lilacs, Scopus and Cochrane, 27 articles were selected, which described the analgesic potential of 16 monoterpenes for relief of chronic pain.

Conclusion: After analyzing the data, it can be suggested that these compounds are strong candidates for the treatment of painful states.

Keywords: Natural products; analgesic potential; chronic diseases; chronic pain; monoterpene; review

Document Type: Review Article

Publication date: June 1, 2018

More about this publication?
  • Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Call for Papers
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content